18065451. ADMINISTRATION OF KYNURENINE DEPLETING ENZYMES FOR TUMOR THERAPY simplified abstract (Board of Regents, The University of Texas System)
Contents
- 1 ADMINISTRATION OF KYNURENINE DEPLETING ENZYMES FOR TUMOR THERAPY
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 ADMINISTRATION OF KYNURENINE DEPLETING ENZYMES FOR TUMOR THERAPY - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Potential Commercial Applications
- 1.9 Possible Prior Art
- 1.10 What are the specific modifications made to the kynureninase protein to enhance its kynurenine degrading capabilities?
- 1.11 How does the technology compare to existing methods for kynurenine depletion in cancer treatment?
- 1.12 Original Abstract Submitted
ADMINISTRATION OF KYNURENINE DEPLETING ENZYMES FOR TUMOR THERAPY
Organization Name
Board of Regents, The University of Texas System
Inventor(s)
George Georgiou of Austin TX (US)
Everett Stone of Austin TX (US)
ADMINISTRATION OF KYNURENINE DEPLETING ENZYMES FOR TUMOR THERAPY - A simplified explanation of the abstract
This abstract first appeared for US patent application 18065451 titled 'ADMINISTRATION OF KYNURENINE DEPLETING ENZYMES FOR TUMOR THERAPY
Simplified Explanation
The abstract describes a patent application related to the use of a protein with kynureninase activity for the treatment of cancer by depleting kynurenine. A modified kynureninase capable of degrading kynurenine is disclosed in the invention.
- Modified kynureninase protein capable of degrading kynurenine
- Treatment of cancer through kynurenine depletion
- Compositions and methods for cancer treatment using the disclosed proteins or nucleic acids
Potential Applications
The technology can be applied in the field of cancer treatment, specifically in targeting kynurenine to inhibit cancer growth and progression.
Problems Solved
This technology addresses the challenge of effectively depleting kynurenine in cancer cells, which is crucial for inhibiting their growth and potentially improving treatment outcomes.
Benefits
The use of the disclosed proteins or nucleic acids can lead to more targeted and effective cancer treatments by depleting kynurenine, a key factor in cancer progression.
Potential Commercial Applications
"Kynurenine Depletion for Cancer Treatment" - This section title is SEO optimized for potential commercial applications of the technology in the field of cancer treatment.
Possible Prior Art
There may be prior art related to kynureninase activity in cancer treatment, but specific information on similar technologies is not provided in the abstract.
Unanswered Questions
What are the specific modifications made to the kynureninase protein to enhance its kynurenine degrading capabilities?
The abstract does not provide details on the specific modifications made to the kynureninase protein for improved kynurenine degradation.
How does the technology compare to existing methods for kynurenine depletion in cancer treatment?
The abstract does not mention a comparison with existing methods for kynurenine depletion in cancer treatment, leaving a gap in understanding the novelty and effectiveness of the disclosed technology.
Original Abstract Submitted
Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with kynurenine depletion using the disclosed proteins or nucleic acids.
